Alimera Sciences Inc (ALIM.O) Quote| Reuters.com
Edition:
United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

1.40USD
24 Jun 2016
Change (% chg)

$-0.09 (-6.04%)
Prev Close
$1.49
Open
$1.43
Day's High
$1.48
Day's Low
$1.37
Volume
2,922,620
Avg. Vol
271,520
52-wk High
$5.15
52-wk Low
$1.37

ALIM.O

Chart for ALIM.O

About

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The... (more)

Overall

Beta: 2.00
Market Cap(Mil.): $63.14
Shares Outstanding(Mil.): 45.10
Dividend: --
Yield (%): --

Financials

  ALIM.O Industry Sector
P/E (TTM): -- 32.69 34.11
EPS (TTM): -0.72 -- --
ROI: -61.28 15.00 14.23
ROE: -- 16.08 15.46

BRIEF-Alimera Sciences reports Q1 GAAP loss per share $0.25

* Alimera sciences announces first quarter 2016 financial results

May 04 2016

Market turmoil drives small biotechs to big pharma

Numerous small biotechnology companies have been all but shut out of the capital markets, leaving many with no choice but to consider a sale to larger peers.

Feb 16 2016

DEALTALK-Market turmoil drives small biotechs to big pharma

Feb 16 Numerous small biotechnology companies have been all but shut out of the capital markets, leaving many with no choice but to consider a sale to larger peers.

Feb 16 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.